Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02949726 · ClinicalTrials.gov registry record · Phase 1
Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT02949726 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 80 participants.
The verdict
NCT02949726, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The goal of this study is to find out which immune molecules, cells, and genes are involved in the development of lymphedema (LE), so that medicines that target them can be considered for treating lymphedema. The hypothesis is that LE is a systemic, autoimmune-like disease that is initiated by inflammatory cytokines induced by surgery, radiation, and possibly chemotherapy in genetically susceptible patients.
Interventions
- DRUG Indocyanine Green (ICG)
- DEVICE Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02949726
The ClinicalTrials.gov registry entry for NCT02949726 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Indocyanine Green (ICG) is the first listed.
NCT02949726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02949726 about?
NCT02949726 is a clinical study titled "Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development". The goal of this study is to find out which immune molecules, cells, and genes are involved in the development of lymphedema (LE), so that medicines that target them can be considered for treating lymphedema. The hypothesis is that LE is a systemic, autoimmune-like disease that is initiated by infla...
What is the current status of trial NCT02949726?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2017-04-24. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT02949726?
The interventions under investigation include: Indocyanine Green (ICG) (DRUG), Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) (DEVICE).
Who is sponsoring clinical trial NCT02949726?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.